Roivant Sciences Stock Net Income
| ROIV Stock | USD 21.91 0.62 2.75% |
As of the 29th of January, Roivant Sciences holds the Semi Deviation of 1.52, coefficient of variation of 679.39, and Risk Adjusted Performance of 0.1147. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Roivant Sciences, as well as the relationship between them. Please check Roivant Sciences coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Roivant Sciences is priced some-what accurately, providing market reflects its current price of 21.91 per share. Given that Roivant Sciences has jensen alpha of 0.2728, we recommend you to check out Roivant Sciences's recent market performance to make sure the company can sustain itself at a future point.
Roivant Sciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 559.9113 | Revenue | Earnings Share (0.99) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -908.1 M | -862.7 M | |
| Net Loss | -410.2 M | -389.7 M | |
| Net Loss | -839.2 M | -797.3 M | |
| Net Loss | (0.21) | (0.20) | |
| Net Income Per E B T | 0.23 | 0.22 |
Roivant | Net Income | Build AI portfolio with Roivant Stock |
Latest Roivant Sciences' Net Income Growth Pattern
Below is the plot of the Net Income of Roivant Sciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Roivant Sciences financial statement analysis. It represents the amount of money remaining after all of Roivant Sciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Roivant Sciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Roivant Sciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (356.73 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Roivant Net Income Regression Statistics
| Arithmetic Mean | (414,674,141) | |
| Coefficient Of Variation | (328.52) | |
| Mean Deviation | 831,194,978 | |
| Median | (1,041,969,000) | |
| Standard Deviation | 1,362,302,966 | |
| Sample Variance | 1855869.4T | |
| Range | 5.4B | |
| R-Value | 0.44 | |
| Mean Square Error | 1597673.2T | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | 118,495,593 | |
| Total Sum of Squares | 29693909.9T |
Roivant Net Income History
Other Fundumenentals of Roivant Sciences
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Roivant Sciences Net Income component correlations
Roivant Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Roivant Sciences is extremely important. It helps to project a fair market value of Roivant Stock properly, considering its historical fundamentals such as Net Income. Since Roivant Sciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Roivant Sciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Roivant Sciences' interrelated accounts and indicators.
Click cells to compare fundamentals
What growth prospects exist in Biotechnology sector? Can Roivant capture new markets? Factors like these will boost the valuation of Roivant Sciences. Anticipated expansion of Roivant directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Roivant Sciences valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Quarterly Earnings Growth (0.96) | Earnings Share (0.99) | Revenue Per Share | Quarterly Revenue Growth (0.65) | Return On Assets |
Roivant Sciences's market price often diverges from its book value, the accounting figure shown on Roivant's balance sheet. Smart investors calculate Roivant Sciences' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Since Roivant Sciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Roivant Sciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Roivant Sciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Roivant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Roivant Sciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Roivant Sciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Roivant Sciences.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Roivant Sciences on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Roivant Sciences or generate 0.0% return on investment in Roivant Sciences over 90 days. Roivant Sciences is related to or competes with Summit Therapeutics, BridgeBio Pharma, Revolution Medicines, Ascendis Pharma, Ionis Pharmaceuticals, EXACT Sciences, and Avidity Biosciences. Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines More
Roivant Sciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Roivant Sciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Roivant Sciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.78 | |||
| Information Ratio | 0.1116 | |||
| Maximum Drawdown | 9.44 | |||
| Value At Risk | (2.84) | |||
| Potential Upside | 4.37 |
Roivant Sciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Roivant Sciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Roivant Sciences' standard deviation. In reality, there are many statistical measures that can use Roivant Sciences historical prices to predict the future Roivant Sciences' volatility.| Risk Adjusted Performance | 0.1147 | |||
| Jensen Alpha | 0.2728 | |||
| Total Risk Alpha | 0.1141 | |||
| Sortino Ratio | 0.1321 | |||
| Treynor Ratio | 0.7195 |
Roivant Sciences January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1147 | |||
| Market Risk Adjusted Performance | 0.7295 | |||
| Mean Deviation | 1.65 | |||
| Semi Deviation | 1.52 | |||
| Downside Deviation | 1.78 | |||
| Coefficient Of Variation | 679.39 | |||
| Standard Deviation | 2.1 | |||
| Variance | 4.43 | |||
| Information Ratio | 0.1116 | |||
| Jensen Alpha | 0.2728 | |||
| Total Risk Alpha | 0.1141 | |||
| Sortino Ratio | 0.1321 | |||
| Treynor Ratio | 0.7195 | |||
| Maximum Drawdown | 9.44 | |||
| Value At Risk | (2.84) | |||
| Potential Upside | 4.37 | |||
| Downside Variance | 3.16 | |||
| Semi Variance | 2.32 | |||
| Expected Short fall | (1.95) | |||
| Skewness | 0.4371 | |||
| Kurtosis | 0.1209 |
Roivant Sciences Backtested Returns
At this stage we consider Roivant Stock to be very steady. Roivant Sciences maintains Sharpe Ratio (i.e., Efficiency) of 0.0843, which implies the firm had a 0.0843 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Roivant Sciences, which you can use to evaluate the volatility of the company. Please check Roivant Sciences' Coefficient Of Variation of 679.39, risk adjusted performance of 0.1147, and Semi Deviation of 1.52 to confirm if the risk estimate we provide is consistent with the expected return of 0.17%. Roivant Sciences has a performance score of 6 on a scale of 0 to 100. The company holds a Beta of 0.42, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Roivant Sciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Roivant Sciences is expected to be smaller as well. Roivant Sciences right now holds a risk of 2.06%. Please check Roivant Sciences maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if Roivant Sciences will be following its historical price patterns.
Auto-correlation | 0.01 |
Virtually no predictability
Roivant Sciences has virtually no predictability. Overlapping area represents the amount of predictability between Roivant Sciences time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Roivant Sciences price movement. The serial correlation of 0.01 indicates that just 1.0% of current Roivant Sciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.01 | |
| Spearman Rank Test | 0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 0.38 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Roivant Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Roivant Sciences reported net income of (356.73 Million). This is 204.53% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 162.48% higher than that of the company.
Roivant Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Roivant Sciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Roivant Sciences could also be used in its relative valuation, which is a method of valuing Roivant Sciences by comparing valuation metrics of similar companies.Roivant Sciences is currently under evaluation in net income category among its peers.
Roivant Sciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Roivant Sciences from analyzing Roivant Sciences' financial statements. These drivers represent accounts that assess Roivant Sciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Roivant Sciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 6.7B | 3.3B | 5.3B | 8.2B | 7.4B | 4.9B | |
| Enterprise Value | 4.8B | 1.5B | 4.1B | 2.1B | 2.5B | 3.9B |
Roivant Sciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Roivant Sciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Roivant Sciences' managers, analysts, and investors.Environmental | Governance | Social |
Roivant Sciences Institutional Holders
Institutional Holdings refers to the ownership stake in Roivant Sciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Roivant Sciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Roivant Sciences' value.| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 7.9 M | Geode Capital Management, Llc | 2025-06-30 | 7.8 M | Ubs Group Ag | 2025-06-30 | 5.1 M | Anchorage Advisors, Llc | 2025-06-30 | 4.8 M | Blackbarn Capital Partners Lp | 2025-06-30 | 4.6 M | Bank Of New York Mellon Corp | 2025-06-30 | 4.5 M | Woodline Partners Lp | 2025-06-30 | 4 M | Whitefort Capital Management, Lp. | 2025-06-30 | 3.9 M | Baker Bros Advisors Lp | 2025-06-30 | 3.8 M | Sb Investment Advisers (uk) Ltd | 2025-06-30 | 60 M | Fmr Inc | 2025-06-30 | 55.5 M |
Roivant Fundamentals
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.12 | ||||
| Operating Margin | (185.95) % | ||||
| Current Valuation | 11.38 B | ||||
| Shares Outstanding | 695.49 M | ||||
| Shares Owned By Insiders | 25.37 % | ||||
| Shares Owned By Institutions | 75.12 % | ||||
| Number Of Shares Shorted | 24.53 M | ||||
| Price To Book | 3.59 X | ||||
| Price To Sales | 770.79 X | ||||
| Revenue | 29.05 M | ||||
| Gross Profit | (581.72 M) | ||||
| EBITDA | (1.1 B) | ||||
| Net Income | (356.73 M) | ||||
| Cash And Equivalents | 1.94 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 100.17 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 6.20 X | ||||
| Book Value Per Share | 6.33 X | ||||
| Cash Flow From Operations | (839.45 M) | ||||
| Short Ratio | 2.42 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Target Price | 27.0 | ||||
| Number Of Employees | 750 | ||||
| Beta | 1.22 | ||||
| Market Capitalization | 15.67 B | ||||
| Total Asset | 5.44 B | ||||
| Retained Earnings | 116.06 M | ||||
| Working Capital | 4.85 B | ||||
| Net Asset | 5.44 B |
About Roivant Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Roivant Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Roivant Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Roivant Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.